retatrutide side effects trial results VisualAbstract: reduces body weight by 17.5% in patients with obesity June 8, 2026: Reckless physicians

While specific guidelines on continuing therapy after HbA1c normalization are lacking, current evidence supports ongoing use of these agents due to their insulin-independent mechanisms of action

It demonstrated a 14% reduction in major cardiovascular events and a 26% reduction in heart attacks specifically for Asian patients.[19] The kidney story gained momentum with the FLOW trial, the first dedicated kidney outcomes study of a GLP-1 medicine

Understanding the regulatory process For researchers less familiar with pharmaceutical regulation, a brief overview of the FDA approval process helps contextualize where retatrutide stands and what comes next

Independent testing from recognized labs like Janoshik provides an unbiased quality check